Table 2

Clinical features of the participants who contributed synovial fluid

Characteristics

RA

OA

Number of participants

30

30

Sex, male/female

6/24

6/24

Age, mean (range)

63.1 (32 to 88)

75.3 (67 to 89)

Disease duration (y), mean (range)

13.0 (0.5 to 50)

NA

Positive anti-CCP antibody, n (%)

10 (83.3%)^¶

NA

ESR (mm), mean (range)

49.6 (4 to 116)

NA

CRP (mg/dl), mean (range)

3.1 (0 to 13.9)

NA

MMP3 (ng/ml), mean (range)

362.7 (43.2 to 800)

NA

DAS28, mean (range)

4.9 (2.2 to 7.1)

NA

SJC, mean (range)

4.9 (0 to 17)

NA

TJC, mean (range)

5.1 (0 to 27)

NA

VAS

52.1 (10 to 95)

NA

Steinbrocker Stage, n

I: 3, II: 3, III: 5, IV: 19

NA

Steinbrocker Class, n

I: 1, II: 22, III: 7, IV: 0

NA

Kellgren/Lawrence grade, n

NA

I: 0, II: 0, III: 11, IV: 19

Medication, n (%)

Prednisolone

20 (67%)

NA

Methotrexate

15 (50%)

NA

Infliximab

3 (10%)

NA

Eternercept

1 (3.3%)

NA

Tocilizumab

0 (0%)

NA

Tacrolimus

2 (6.7%)

NA

Salazosulfapyridine

8 (27%)

NA

Bucillamine

6 (20%)

NA

Mizoribine

1 (3.3%)

NA

Gold

2 (6.7%)

NA

CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentaition ratio; MMP-3, metalloproteinase-3; NA, not applicable; OA, osteoarthritis; RA, rheumatoid arthritis; SJC, swollen joint count score; TJC, tender joint count; VAS, visual analogue scale of general health.

¶anti-CCP antibodies of 10 patients were positive among 12 patients examined.

Murata et al. Arthritis Research & Therapy 2010 12:R86   doi:10.1186/ar3013